Composition for prevention or treatment of hair loss including hapln1

A technology for a composition and cosmetic composition, which is applied in the directions of pharmaceutical combinations, medical preparations containing active ingredients, hair care, etc., can solve problems such as no disclosure confirmation, no mention of the effect of preventing or treating hair loss, etc.

Pending Publication Date: 2021-12-10
HAPLNSCI INC
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Also, U.S. Patent Registration No. 8,334,136 lists more than twenty genes that interfere with cell adhesion in dermal dermal papilla cells, and mentions the possibility that hair follicle formation can be promoted by maintaining or increasing the expression of the genes , however, it only revealed HAPLN1 as one of the twenty genes, and did not reveal results confirming whether the expression of these genes actually promotes hair follicle formation
[0011] Therefore, the document mentions only HAPLN1 as one of the biomarkers for identifying dermal dermal papilla cells or dermal sheath cells or distinguishing them from other cells, and does not mention when HAPLN1 protein is directly administered as an active ingredient Shown to be effective in preventing or treating hair loss
Moreover, there has been no study so far that among the many pathways in the hair growth cycle, the activation of the ERK1 / 2 signal transduction pathway activated by TGF-β protein is effective for the treatment of hair loss, especially, HAPLN1 acts on germinal stromal cells (germinal matrix cell) and activate the pathway to promote hair growth

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for prevention or treatment of hair loss including hapln1
  • Composition for prevention or treatment of hair loss including hapln1
  • Composition for prevention or treatment of hair loss including hapln1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Confirmation of HAPLN1 protein and HAPLN1 mRNA expression in each hair growth cycle

[0061] In this example, the expression of HAPLN1 protein in each hair growth cycle was confirmed by using mouse skin.

[0062] The mouse skins of 23 days after birth (initial growth period), 32 days after birth (growth period), 40 days after birth (catagen) and 44 days after birth (telogen phase) were taken, and the Implementation of fresh freezing (fresh frozen). Skin tissue sections were made with a thickness of 8um, and the presence or absence of HAPLN1 protein was detected using HAPLN1 (Abcam, USA) antibody. Immunofluorescence was performed according to the general experimental method.

[0063] The result is as Figure 4 As shown, it was confirmed that HAPLN1 was expressed considerably in the growth-phase germinal stromal cells, and conversely, the expression decreased in the catagen and telogen phases.

[0064] Next, in order to identify cells in which HAPLN1 is produced, HAPL...

Embodiment 2

[0068] Confirmation of an increase in TβRII protein by HAPLN1 in human germinal stromal cells

[0069] In this example, it was confirmed whether HAPLN1 blocks the degradation of TβRII to increase its amount.

[0070] Human hair stromal cells were treated with HAPLN1 at various concentrations. Specifically, the human hair germinal matrix cell (human hair germinal matrix cell; HHGMC) was 5.0×10 4 Each well was inoculated on a poly-D-lysine 6-well plate and incubated for 24 hours. After 24 hours, the medium was removed and replaced with new medium without serum. HAPLN1 treatment was performed at 0 ng / mL, 5 ng / mL, 10 ng / mL, 20 ng / mL and cultured for 24 hours. After the cells were collected, lysisbuffer (25mM Tris-HCL, 1mM EDTA, 0.1% Triton-X100, phosphatase inhibitor, and protease inhibitor) was put into, and all cells were disrupted by sonication. cell. TβRII in this sample was measured by using Western blotting. The optical concentration of each TβRII relative to GAPDH was...

Embodiment 3

[0074] Confirmation of an increase in TβRII protein induced by HAPLN1 and / or HA in human germinal stromal cells

[0075] It has been hypothesized that HAPLN1 does not directly act on TβRII in the TGF-β signal transduction pathway but images TβRII by stabilizing HA. To confirm this, an experiment in which HAPLN1 and HA were simultaneously treated was performed.

[0076] Human hair stromal cells were divided into 5.0×10 4 Each well was inoculated in a poly-D-lysine 6-well plate and incubated for 24 hours. After 24 hours, the medium was removed and replaced with new medium without serum. Treatment with HAPLN1 at 25 ng / mL and HA at 25 ug / mL was followed by TGF-β2 (2 ng / mL) treatment 1 hour later. After 23 hours, cells were collected and put into lysis buffer (25nM Tris-HCL, 1mM EDTA, 0.1% Triton-X100, phosphatase inhibitors and protease inhibitors), and all the cells were disrupted by sonication. TβRI and TβRII in this assay were measured by using Western blotting. The optical...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of hair loss, the composition comprising hyaluronan and proteoglycan link protein 1 (HAPLN1) as an active ingredient. When administered, the HAPLN1 protein of the present invention promotes proliferation of hair germinal matrix cells through the Ras-ERK1 / 2 signaling pathway activated by TGF-beta protein, thereby growing hair.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing or treating hair loss, which comprises hyaluronan and proteoglycan link protein 1 (HAPLN1) as an active ingredient. The HAPLN1 protein of the present invention promotes the proliferation of germinal stromal cells to grow hair through the ERK1 / 2 signal transduction pathway (ie, non-canonical signal transduction pathway) activated by TGF-β protein when administered. Background technique [0002] About 35 million men and 25 million women worldwide suffer from hair loss, and the number of patients with hair loss shows a tendency to increase every year. Hair has various functions related to appearance, heat resistance, protection of the scalp, buffering friction, etc. Of these, hair is particularly directly related to self-esteem and sociality, and therefore, hair management is a hot topic for many on aesthetic grounds. [0003] Human hair is an aggregate of about 100,000 individ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P17/14A61K8/64A61Q7/00
CPCA61K38/17A61P17/14A61K8/64A61Q7/00A61K8/735A61K31/728A61K38/1709A61K2300/00A61K38/00A61K38/1741
Inventor 金大敬河海赞张智旻申仁澈白文正周丹
Owner HAPLNSCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap